Callan Family Office LLC Makes New $595,000 Investment in Pfizer Inc. (NYSE:PFE)

Callan Family Office LLC acquired a new stake in shares of Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 22,414 shares of the biopharmaceutical company’s stock, valued at approximately $595,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. PSI Advisors LLC raised its position in Pfizer by 1.4% in the 4th quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company’s stock worth $738,000 after purchasing an additional 385 shares during the last quarter. Waddell & Associates LLC boosted its holdings in Pfizer by 1.6% in the third quarter. Waddell & Associates LLC now owns 24,978 shares of the biopharmaceutical company’s stock valued at $723,000 after acquiring an additional 388 shares during the last quarter. Patriot Financial Group Insurance Agency LLC increased its position in Pfizer by 1.0% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company’s stock worth $1,027,000 after purchasing an additional 391 shares during the period. D Orazio & Associates Inc. lifted its position in Pfizer by 5.5% during the 4th quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company’s stock valued at $200,000 after purchasing an additional 391 shares during the period. Finally, Lipe & Dalton boosted its stake in shares of Pfizer by 17.7% in the 4th quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 400 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

PFE stock opened at $26.71 on Monday. The stock has a 50-day moving average price of $26.30 and a two-hundred day moving average price of $27.23. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The stock has a market cap of $151.35 billion, a PE ratio of 18.94, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer’s quarterly revenue was up 24.7% on a year-over-year basis. During the same period last year, the company earned $0.10 earnings per share. Equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 7th. Stockholders of record on Friday, January 24th were given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.44%. The ex-dividend date was Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is currently 121.99%.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of analyst reports. Wolfe Research initiated coverage on Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target on the stock. Truist Financial cut their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. UBS Group decreased their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Citigroup cut their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Finally, StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Pfizer has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is currently owned by corporate insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.